AHCO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Adapthealth Corp (AHCO) is not a strong buy for a beginner investor with a long-term focus at this time. The company's financial performance has significantly deteriorated, and recent analyst ratings have shown lowered price targets. While there is some insider and hedge fund buying activity, the lack of positive news, weak financials, and mixed technical indicators suggest holding off on investment for now.
The MACD is positive and expanding (0.18), indicating bullish momentum. The RSI (75.869) is in the neutral zone but nearing overbought levels. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key resistance levels are at 11.48 and 11.938, while support levels are at 9.998 and 9.54. However, the stock's price has been relatively stagnant with minor fluctuations.
Insiders and hedge funds are significantly increasing their buying activity, with insider buying up 20,850.77% and hedge fund buying up 1,321.21% in recent periods. The stock has a 70% chance to increase by 5.55% in the next week based on historical patterns.
There is no recent news or event-driven catalyst to support a bullish case.
In Q4 2025, revenue dropped to $846.29M (-1.21% YoY), net income fell to -$100.08M (-317.56% YoY), EPS dropped to -$0.74 (-317.65% YoY), and gross margin decreased to 19.17% (-45.68% YoY). These figures indicate a significant decline in the company's financial health.
Deutsche Bank and Canaccord both lowered their price targets recently. Deutsche Bank reduced it to $9.50 with a Hold rating, while Canaccord lowered it to $14 but maintained a Buy rating. Analysts cited operational improvements but highlighted challenges related to debt settlements and forward investment decisions.
